Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CARD-IO - CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

NCT06605833 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT06605833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06605833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CARD-IO - CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Observational
Overall status
Enrolling by invitation
Start date
September 26, 2025
Completion date
September 30, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii or iv